Sema4, a Mount Sinai spinout, launches with a focus on genomics

Pronounced “semaphore,” the company will utilize genomic and clinical data to transform overall clinical diagnostics. By combining everything from predictive modeling to open access data, it aims to be able to better treat and diagnose diseases.

Spotlight

Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More